Anavex to Present Data on ANAVEX 2-73, Lead Compound for Alzheimer’s Disease, at Japan Neuroscience Society Special Symposium
Anavex Presents Data on Neuroprotective Evidence for ANAVEX 2-73, Lead Compound for Alzheimer’s Disease
Preclinical development of new tetrahydrofuran derivatives targeting the sigma-1 chaperone protein as neuroprotectants in Alzheimer’s disease.
The novel tetrahydrofuran derivative ANAVEX2-73 attenuated GSK-3β activation and Tau hyperphosphorylation in a nontransgenic Alzheimer’s disease model in mice.
